(BIO) Bio-Rad Laboratories, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BIO) Bio-Rad Laboratories, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Bio-Rad Laboratories, Inc. BCG Matrix is a ready-made strategic tool used to assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Droplet Digital PCR QX200 and QX600
Bio-Rad Laboratories, Inc.’s Droplet Digital PCR QX200 and QX600 sit in the Stars quadrant: Bio-Rad remains a top name in digital PCR, and the market keeps growing for absolute quantification and rare-target detection. The systems support up to about 20,000 droplets per sample, while QX600 adds six-plex capability, lifting strategic value. They also drive high-margin reagent pull-through after each instrument sale.
ddPCR assay kits and consumables
In fiscal 2025, Bio-Rad Laboratories, Inc. kept growing ddPCR pull-through as each system sale adds recurring reagent demand, so ddPCR assay kits and consumables fit a Star. The category scales with the installed base and repeat use, which supports steady, high-margin revenue after placement. In Bio-Rad Laboratories, Inc. 2025 results, recurring lab demand stayed central to the model, and that is the profit engine here.
Bio-Plex multiplex immunoassay systems
Bio-Plex multiplex immunoassay systems can measure up to 100 analytes in a single sample, which fits biomarker discovery and multi-analyte research well. Multiplex testing keeps growing in translational and academic labs because it saves sample volume and speeds data generation. Bio-Rad’s installed-base support and specialty positioning help keep reagent pull-through strong, which supports Star status.
Biopharma workflow tools for protein purification
Biopharma workflow tools for protein purification fit Bio-Rad Laboratories, Inc. as a Star: biologics growth keeps lifting demand for purification and characterization, and Bio-Rad sells chromatography and workflow products that ride that need.
The segment benefits from premium consumables pull-through, since each run needs resins, columns, and related kits, so recurring revenue can scale with biologics output.
Bio-Rad’s Life Science segment remains tied to this trend, with 2025 demand supported by bioprocessing and QC use cases rather than one-off instrument sales.
- Biologics growth supports steady demand.
- Chromatography drives recurring consumables use.
- Workflow tools support premium pricing.
Digital biology research platforms
Bio-Rad Laboratories, Inc.’s digital biology platforms are a Star because they bundle instruments, assays, and workflow reagents, so lab adoption can lift repeat sales. In 2025, Bio-Rad Laboratories, Inc. generated about $2.56 billion in net sales, showing a base big enough to fund this growth bet.
The stack is sticky: once a lab installs the platform, it tends to keep buying consumables and upgrades, which supports margin over time. Bio-Rad Laboratories, Inc. also serves a large global life science market, and that helps the digital biology mix scale as customers add more automated and data-linked workflows.
- Platform sales grow with lab usage
- Consumables support recurring revenue
- 2025 net sales: about $2.56 billion
- Best fit for high-growth, high-share Star
Bio-Rad’s Growth Engines: ddPCR and Bio-Plex Keep Reagents Flowing
Bio-Rad Laboratories, Inc.’s Stars are ddPCR, Bio-Plex, and biopharma workflow tools because they pair strong growth with sticky consumable pull-through. In fiscal 2025, Bio-Rad Laboratories, Inc. posted about $2.56 billion in net sales, and the installed base keeps driving repeat reagent demand.
| Star | Why it fits | 2025 note |
|---|---|---|
| ddPCR | High growth | Recurring reagents |
| Bio-Plex | 100-analyte multiplexing | Strong pull-through |
What is included in the product
Detailed Word Document
Bio-Rad’s BCG Matrix maps its diagnostics and life science units to guide invest, hold, or divest decisions.
Editable Excel File
One-page Bio-Rad Laboratories BCG Matrix that quickly spots winners and laggards for faster portfolio decisions
Reference Sources
Provides a traceable source trail for Bio-Rad Laboratories, Inc., boosting credibility and helping decision-makers verify assumptions fast.
Cash Cows
HbA1c testing on VARIANT II Turbo and D-10
Bio-Rad Laboratories, Inc.'s HbA1c testing on VARIANT II Turbo and D-10 is a classic Cash Cow: diabetes monitoring is mature, but the installed base keeps reagent pull-through steady. HbA1c tracks the prior 2-3 months of glucose, so labs run it again and again, which supports recurring, high-margin sales even in low-growth markets.
Immunohematology systems for blood typing
Bio-Rad Laboratories, Inc.’s immunohematology blood-typing business fits Cash Cows because transfusion testing is a tightly regulated, replacement-driven market with sticky lab placements. Its systems and reagents are embedded in hospital and reference labs, so revenue keeps coming from repeat consumables rather than heavy new capex. In Bio-Rad Laboratories, Inc.’s FY2025 mix, this type of installed-base model supports steady cash flow with limited growth spend.
Quality control and calibration products
Quality control and calibration products are a Cash Cow for Bio-Rad Laboratories, Inc. Clinical labs buy them again and again to keep analyzers accurate and meet CAP/CLIA rules, so demand tracks routine test volume, not one-time installs. This makes the franchise steady and margin-friendly, with recurring revenue from a mature market.
Electrophoresis consumables and blotting reagents
Electrophoresis consumables and blotting reagents are classic cash cows for Bio-Rad Laboratories, Inc.: they serve a wide installed base, sell in repeat cycles, and face low switching once labs standardize workflows. Bio-Rad’s fiscal 2025 net sales were about $2.6 billion, so these steady, replenishment-led products help support reliable cash flow even without fast growth.
- Broad installed base
- Frequent repeat orders
- Low growth, strong retention
- Steady cash generation
Protein assay reagents and standard lab chemicals
Bio-Rad Laboratories, Inc.'s protein assay reagents and standard lab chemicals fit the Cash Cows bucket: they are used in daily lab workflows, face a mature and crowded market, and still benefit from a sticky installed base. These products usually generate steady cash rather than fast growth, helping fund Bio-Rad's higher-growth bets. The value here is durability, not expansion.
- High routine use
- Stable, recurring cash flow
- Low growth, strong retention
Bio-Rad’s Cash Cows Keep Repeating Revenue Coming
Bio-Rad Laboratories, Inc.'s Cash Cows are mature, repeat-use products that keep money coming in from installed lab systems. FY2025 net sales were about $2.6 billion, and these franchises lean on recurring consumables, not heavy new hardware sales. HbA1c, blood typing, QC, and electrophoresis are stable because labs reorder them often. The cash comes from routine use and sticky placements.
| Cash Cow | Why it matters |
|---|---|
| HbA1c | Repeat reagent pull-through |
| Blood typing | Sticky installed base |
| QC and calibration | Recurring compliance demand |
| Electrophoresis | High repeat consumable use |
What You See Is What You Get
Bio-Rad Laboratories, Inc. Reference Sources
This preview shows the exact Bio-Rad Laboratories, Inc. BCG Matrix report you’ll receive after purchase. The final file is the same fully formatted document—no mockups, no watermarks, and no hidden changes. Once purchased, it’s ready for immediate download, use, and presentation.
Dogs
Legacy slab-gel electrophoresis hardware
Bio-Rad Laboratories, Inc.'s legacy slab-gel electrophoresis hardware fits the Dogs bucket: it serves a mature niche with slow replacement demand and little room to scale. Buyers are shifting to automated, digital workflows, so older manual formats keep losing share. With Bio-Rad Laboratories, Inc. generating about $2.6 billion of revenue in 2024, this hardware line looks low-growth and weak on expansion potential.
Older standalone thermal cyclers
Older standalone thermal cyclers fit Dogs: basic PCR tools sit in a crowded, price-sensitive market, while newer molecular platforms pull spend to digital PCR and higher-throughput systems. Bio-Rad Laboratories, Inc.'s 2025 mix still shows stronger demand in advanced workflows than in legacy hardware, so these units have low growth and weak differentiation.
Low-end imaging and documentation systems
Bio-Rad Laboratories, Inc.’s low-end imaging and documentation systems fit the Dogs box: basic lab imaging is now commoditized, so pricing stays under pressure and margins stay thin. In Bio-Rad Laboratories, Inc.’s 2025 mix, these mature tools are unlikely to justify major new capital, especially versus higher-return life science platforms. They usually get maintenance funding, not growth spend, unless a clear replacement cycle opens up.
Commodity food-testing assay lines
Commodity food-testing assay lines fit Bio-Rad Laboratories, Inc. as a "Cash Cow": food safety demand stays steady, but mature formats face heavy competition and slower growth than digital molecular workflows. In fiscal 2025, Bio-Rad Laboratories, Inc. reported about $2.57 billion in net sales, and this kind of line can absorb R&D and sales spend without building clear share gains.
- Stable demand, weak growth
- High competition, low differentiation
- Resource drag versus molecular assays
Small accessory hardware with limited scale
Small accessory hardware fits Bio-Rad Laboratories, Inc.’s Dogs bucket because these add-ons have low ticket sizes and little strategic pull. Bio-Rad’s 2025 net sales were about $2.56 billion, but accessories are not a main growth engine; they mostly support core systems and lab workflows. In BCG terms, they act like low-share, low-growth fillers, so capital use should stay tight.
- Low price, low scale
- Add-on value, not growth
- Keep inventory lean
- Prioritize core platforms
Bio-Rad’s Legacy Tools Are Low-Growth Dogs
Bio-Rad Laboratories, Inc.’s Dogs are legacy tools with flat demand and weak pricing power. By fiscal 2025, net sales were about $2.57 billion, but these lines still lag higher-growth digital PCR and automated workflows. They need only maintenance spending, not heavy capital, unless a clear replacement cycle appears.
| Item | Signal | 2025 view |
|---|---|---|
| Legacy tools | Low growth | Dogs |
| Net sales | Scale | $2.57B |
| Spend | Capital use | Lean |
Question Marks
Single-cell analysis workflows
Single-cell analysis workflows fit a Question Mark: the market is growing fast, but adoption is still early and crowded. Bio-Rad Laboratories, Inc. has a real presence, yet it needs more scale, platform wins, and workflow stickiness to turn this into a stronger 2025-2026 growth engine. If Bio-Rad does not keep investing in single-cell tools and consumables, the category can stay niche instead of becoming a material profit pool.
NGS sample prep and QC
Next-generation sequencing sample prep and QC sits in a high-growth field: Bio-Rad Laboratories, Inc. reported fiscal 2025 revenue of about $2.6 billion, while its life science segment benefited from growing demand in research tools. Bio-Rad has useful adjacent products, but it is not a category leader in sequencing platforms. That makes this a Question Mark: the market is expanding, but share is still building.
Clinical molecular diagnostics beyond HbA1c
Clinical molecular diagnostics beyond HbA1c is a Question Mark for Bio-Rad Laboratories, Inc. because labs keep broadening molecular panels, but Bio-Rad still leads more clearly in diabetes and transfusion than in this wider niche. In 2025, Bio-Rad posted about $2.6 billion in sales, and this segment likely needs heavy R&D and commercial spend to win share. That makes it a high-growth, high-investment bet with uncertain payoff.
Bioprocess analytics software
Bioprocess analytics software fits a Question Mark because biomanufacturing demand is rising in biologics and cell therapies, but Bio-Rad Laboratories, Inc. still has a smaller footprint here than in its core diagnostics. The category can scale fast through recurring software and data workflows, yet Bio-Rad Laboratories, Inc. has not built the same market power it holds in PCR and quality control tools.
High-growth biomanufacturing use case.
Software scales well, but share is thin.
Needs more investment to win share.
Lab automation and connected workflow tools
Lab automation is a Question Mark for Bio-Rad Laboratories, Inc.: demand is rising in research and clinical labs, but share is still unclear in a crowded market. The global lab automation market was estimated at about $7B in 2025 and is growing at high-single-digit rates, so the pool is real. But winning needs steady R&D spend and tighter integration across instruments, software, and consumables.
- Growing demand, uncertain share
- Crowded field, tough switching costs
- Needs capital and product integration
Bio-Rad’s Growth Bets: Big Potential, Still Early
Bio-Rad Laboratories, Inc. Question Marks are growth niches with weak share: single-cell analysis, next-gen sequencing sample prep, broader molecular diagnostics, bioprocess analytics software, and lab automation. In fiscal 2025, Bio-Rad Laboratories, Inc. generated about $2.6 billion in revenue, so these bets matter but still need more scale and R&D to move from promise to profit.
| Area | Signal |
|---|---|
| Single-cell | High growth, early adoption |
| Sequencing prep | Growing market, low share |
| Lab automation | ~$7B market in 2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.